Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.41, read 2026-11-01
Ethical does not pass the values gate
Price23.26 USD
Fair value23.75
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-29Read Markup20.73+12.2% to today ✓Distribution gives way to Markup first Markup read since September
2026-10-02Read Distribution20.23+15.0% to today Markup gives way to Distribution after a 16% slide in 5 weeks
2026-08-25Read Markup24.16-3.7% to today Markdown gives way to Markup after an 11% rise in 8 weeks
2026-07-02Read Markdown21.68+7.3% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Campbell's Company (The) holds its Markup at $23.26. Consolidating, no directional conviction, held for 7 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 7 days
Price at the screen
$23.26
Valuation
16.76 trailing · 11.96 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.05
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
48.42%
Below 33%
Interest-bearing debt is 48.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.03%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
4.52%
Below 49%
Money owed to the company is 4.5% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Campbell's Company (The)'s business is in a permissible area, but its interest-bearing debt is about 48% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CPB's ethical verdict changes
Today CPB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly an 8% discount to our $23.75 fair value, narrow competitive moat.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 2.1% discount to the base estimate.
Where our models see it going: fair-value estimate $23.75, with a range of $23.75 to $43.92, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Campbell's Soup Sells Less While Debt Mounts
Picture the red and white can that once sat in every kitchen cupboard. Campbell's still shifts tins and snacks, yet revenue is falling 4% and the balance sheet carries more debt than our ethical screen will accept, so we pass.
The 11 times forward earnings multiple looks modest against 15% ROE and a narrow moat, but the price sits 14% above our fair value and seventeen analysts see only modest upside to 20 dollars. Defensive food names rarely reward investors who ignore the top line.
Heavy leverage that fails the debt test plus shrinking sales turn the low multiple into a warning rather than an opportunity. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CPB trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$23.26+12.2%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $21.
2026-10-29Markup · changed$20.73+7.1%Entry 17
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $21.
2026-10-22Distribution$19.35+0.7%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $21.
2026-10-15Distribution$19.21-5.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $21.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 16.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $21.
2026-09-03Markup$24.16+0.0%Entry 13
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-02Markup$24.16+0.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-01Markup$24.16+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31Markup$24.16+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30Markup$24.16+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 6%. The street (17 analysts) rates it hold, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
